Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy.
Medical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria of Bologna, DIMEC, University of Bologna, Via Massarenti 9, 40138, Italy.
Crit Rev Oncol Hematol. 2023 Dec;192:104146. doi: 10.1016/j.critrevonc.2023.104146. Epub 2023 Sep 28.
Clinical practice guidelines for the management of cholangiocarcinoma (CCA)/biliary tract cancer recommend genomic profiling to guide treatment decisions. Variable access to such profiling across Italy means many oncologists are unfamiliar with when and how to conduct genetic testing and prescribe targeted treatments.
A Scientific Board of Italian oncologists who treat CCA (the authors) developed recommendations, based on recent clinical evidence, for using molecular testing in diagnosing, assessing, and treating CCA in Italy. The Delphi process was used to reach consensus on these recommendations among 38 Italian oncologists. Consensus was considered to be met if ≥ 66.7 % of the panel agreed or strongly agreed with each statement.
Consensus was reached on 28 statements across four themes: (1) epidemiology and risk factors; (2) diagnosis, including molecular diagnosis; (3) treatment selection; and (4) treatment safety.
These recommendations should aid Italian clinicians in selecting appropriate treatment options for their patients.
胆管癌（CCA）/胆道癌管理的临床实践指南建议进行基因组分析，以指导治疗决策。意大利各地获得此类分析的机会不同，这意味着许多肿瘤学家不熟悉何时以及如何进行基因检测和规定靶向治疗。
意大利治疗 CCA 的肿瘤学家科学委员会（作者）根据最近的临床证据，制定了在意大利使用分子检测诊断、评估和治疗 CCA 的建议。德尔菲法用于在 38 名意大利肿瘤学家中就这些建议达成共识。如果小组中≥66.7%的成员同意或强烈同意每个陈述，则认为达成共识。
在四个主题（1）流行病学和危险因素；（2）诊断，包括分子诊断；（3）治疗选择；和（4）治疗安全性方面达成了 28 项共识。
这些建议应有助于意大利临床医生为其患者选择合适的治疗方案。
